GW4064: Selective Non-Steroidal FXR Agonist for Metabolic Research

Executive Summary: GW4064 is a highly selective, non-steroidal FXR agonist (EC₅₀: 15 nM in isolated receptor assays) used primarily in metabolic and liver disease research (APExBIO). It modulates cholesterol, triglyceride, and bile acid metabolism by activating FXR, a nuclear receptor central to metabolic regulation (Zhou et al., 2025). GW4064 has demonstrated efficacy in lowering serum triglycerides and VLDL in animal models but is limited by poor aqueous solubility and UV instability (GSKchem). Recent studies highlight its role in regulating the FXR/TLR4 pathway and ferroptosis, clarifying mechanisms underlying fibrosis and metabolic disorders. The compound is supplied as a solid, is insoluble in water and ethanol but freely soluble in DMSO (≥24.7 mg/mL), and should be stored at -20°C for optimal stability (APExBIO).

Biological Rationale

Farnesoid X receptor (FXR), also known as NR1H4, is a nuclear receptor expressed abundantly in liver, intestine, kidney, and adrenal tissues. FXR regulates bile acid synthesis, lipid metabolism, and glucose homeostasis. Its activation suppresses bile acid synthesis by repressing CYP7A1 and modulates hepatic triglyceride and cholesterol levels (Zhou et al., 2025). Dysregulation of FXR signaling is implicated in metabolic disorders such as non-alcoholic fatty liver disease (NAFLD), dyslipidemia, and liver fibrosis. GW4064, developed as a potent and selective FXR agonist, enables researchers to interrogate these pathways with high specificity. Its use has clarified the involvement of FXR in processes such as collagen deposition and ferroptosis in hepatic stellate cells (Ponesimodapis.com). This article extends prior guidance by integrating recent findings on the FXR/TLR4/ferroptosis axis.

Mechanism of Action of GW4064

GW4064 binds to the ligand-binding domain of FXR with high affinity (EC₅₀ = 15 nM, isolated assay) and induces conformational changes that facilitate coactivator recruitment. This ligand-induced activation leads to transcriptional regulation of target genes involved in bile acid transport (e.g., BSEP/ABCB11), synthesis (e.g., CYP7A1), and lipid metabolism (e.g., ApoC-II, ApoC-III). In human FXR-transfected cells, GW4064 displays an EC₅₀ of 90 nM. Animal models (e.g., KK-Ay, ob/ob, SHP^+/+ mice) treated with GW4064 exhibit reduced serum triglycerides and VLDL secretion. Mechanistically, FXR activation also downregulates TLR4 expression and enhances ferroptosis features, as shown in LX-2 hepatic stellate cells exposed to nickel oxide nanoparticles (NiONPs) (Zhou et al., 2025).

Evidence & Benchmarks

• GW4064 activates FXR with an EC₅₀ of 15 nM in isolated receptor assays and 90 nM in human FXR-transfected cell assays (APExBIO).
• In SHP^+/+ mice, GW4064 administration lowers serum triglyceride levels and VLDL secretion, supporting its role in lipid modulation (GSKchem).
• GW4064 reduces collagen I/III deposition and promotes ferroptosis in LX-2 cells exposed to NiONPs, indicating FXR-mediated antifibrotic effects (Zhou et al., 2025).
• GW4064 is insoluble in water and ethanol, but dissolves in DMSO at ≥24.7 mg/mL; storage at -20°C is recommended for stability (APExBIO).
• Structural features include a stilbene pharmacophore, which is associated with UV sensitivity and potential toxicity, limiting in vivo translation (GSKchem).
• FXR activation by GW4064 inhibits TLR4 expression and enhances ferroptosis markers in hepatic stellate cells, clarifying molecular mechanisms in fibrosis (Zhou et al., 2025).

This article updates and extends the mechanistic focus of GW4064: Unraveling FXR Signaling by providing new evidence on FXR/TLR4/ferroptosis interplay in fibrosis models.

Applications, Limits & Misconceptions

GW4064 is deployed as a research tool to probe FXR function in metabolic disorders, liver fibrosis, and bile acid metabolism. Its validated selectivity profile underpins rigorous pathway studies and pharmaceutical screening. However, its use is restricted to in vitro and preclinical models due to poor solubility and UV instability. The presence of the stilbene pharmacophore introduces potential toxicity risks, precluding therapeutic development (APExBIO). For practical laboratory workflows, GW4064 is best used in DMSO-based solutions, with short-term aliquots to minimize degradation. For scenario-driven deployment, see GW4064 (SKU B1527): Enabling Reliable FXR Pathway Research, which this article updates by emphasizing recent antifibrotic and ferroptosis-related findings.

Common Pitfalls or Misconceptions

• GW4064 is not suitable for clinical or therapeutic use due to its solubility, stability, and toxicity profile.
• It does not act on other nuclear receptors with significant potency; its selectivity for FXR is validated, minimizing off-target effects.
• GW4064 solutions in aqueous buffers or ethanol are not recommended due to insolubility and precipitation risk.
• Long-term exposure to light (especially UV) degrades GW4064, reducing experimental reliability.
• Results obtained in rodent or cell models may not directly extrapolate to human clinical outcomes.

Workflow Integration & Parameters

For optimal use of GW4064, dissolve the compound in DMSO (minimum 24.7 mg/mL) and store aliquots at -20°C. Prepare working solutions fresh before each experiment to avoid degradation. Use light-opaque containers to minimize UV-induced breakdown. In cell-based assays, typical concentrations range from 0.1 μM to 10 μM, depending on model sensitivity (APExBIO). For metabolic and fibrosis studies, GW4064 can be combined with TLR4 inhibitors or ferroptosis modulators to dissect pathway interactions (Zhou et al., 2025). For troubleshooting and protocol optimization, GW4064: Selective FXR Agonist for Metabolic Disorder Research provides detailed workflows, which this article updates with benchmarks for ferroptosis and collagen deposition endpoints.

Conclusion & Outlook

GW4064 remains the gold-standard non-steroidal FXR agonist for dissecting cholesterol, triglyceride, and bile acid metabolism in preclinical research. Its robust selectivity profile and mechanistic clarity enable reproducible investigation of the FXR signaling pathway, including the FXR/TLR4/ferroptosis axis in fibrosis. Despite its limitations in clinical translation, GW4064 is indispensable for metabolic disorder studies and pharmacological screening. Ongoing efforts to develop more stable, less toxic FXR agonists build upon insights obtained using GW4064. For detailed specifications and ordering, refer to the APExBIO GW4064 product page.